<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001941</url>
  </required_header>
  <id_info>
    <org_study_id>000030</org_study_id>
    <secondary_id>00-C-0030</secondary_id>
    <nct_id>NCT00001941</nct_id>
    <nct_alias>NCT00020020</nct_alias>
  </id_info>
  <brief_title>Anti-Tac for Treatment of Leukemia</brief_title>
  <official_title>A Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax(Trademark)) in the Therapy of Tac-Expressing Adult T-Cell Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to determine: (1) the toxicity and maximum tolerated dose (MTD)
      of humanized anti-Tac (daclizumab), (Zenapax(Registered Trademark)) in patients with adult
      T-cell leukemia/lymphoma (ATL); (2) to define the dose of Zenapax(Registered Trademark)
      required to saturate interleukin 2 receptor alpha (IL-2R) alpha in patients with ATL; (3)
      determine the clinical response to humanized (Hu) anti-Tac (Zenapax(Registered Trademark) of
      patients with Tac-expressing adult T-cell leukemia; and (4) determine the serum dieaway curve
      (pharmacokinetics) of infused humanized (Hu)-anti-Tac in patients who have ATL. This study
      represented an extension of Metabolism Branch National Cancer Institute (NCI) protocols
      utilizing modifications of the original murine anti-Tac monoclonal antibody (mAb) developed
      by our group for the treatment of ATL. The scientific basis for these therapeutic studies is
      that the leukemic cells of patients with ATL express abnormally high levels of the Tac
      antigen (IL-2R alpha) on their surface whereas resting normal cells including normal T-cells
      of the patients do not. One presumed mode of action of Hu-anti-Tac in the treatment of ATL
      involves the interruption of the interaction of interleukin 2 (IL-2) with its growth factor
      receptor. To be effective in this goal we must maintain saturation of the IL-2 receptors
      (IL-2R) with humanized anti-Tac thereby preventing IL-2 mediated proliferation and yielding
      cytokine deprivation and apoptotic cell death of the leukemic cells. Eligible patients with
      ATL were treated with escalating doses of Zenapax(Registered Trademark) between groups in the
      Clinical Center of the National Institutes of Health (NIH). Groups of patients received
      sufficient Zenapax(Registered Trademark) to yield saturation of the IL-2 receptor for a
      period of 17 weeks. Clinical response was evaluated using routine immunological and clinical
      evaluation and by monitoring the saturation of the IL-2R and the absolute number of residual
      circulating malignant cells by fluorescence activated cell sorting (FACS) analysis using two
      fluorochrome-labeled non-crossreacting antibodies to the IL-2 receptor, anti-Tac and 7G7/B6,
      as well as antibodies to cluster of differentiation 3 (CD3), cluster of differentiation 4
      (CD4), cluster of differentiation 7 (CD7), and cluster of differentiation 8 (CD8).
      Furthermore, responses were evaluated in patients with leukemia by Southern blot analysis of
      the arrangement of the T-cell receptor genes and human T-lymphotropic virus type 1 (HTLV-I)
      integration. Finally, in select patients, to define the pharmacokinetics of the therapeutic
      antibody, had planned to monitor the serum levels of the infused Hu-anti-Tac
      (Zenapax(Registered Trademark)) as a function of time. This study is an essential element of
      our program involving IL-2R-directed therapeutic studies. If as anticipated the therapy with
      humanized anti-Tac yields some partial and complete remissions in patients with ATL, we will
      propose that it be used as a single agent for patients with smoldering and chronic ATL and in
      association with chemotherapeutic agents to provide a novel approach for the treatment of
      acute and lymphoma forms of ATL. We also plan a future clinical trial where tentative plans
      also had been made to evaluate the efficacy and toxicity in ATL patients of saturating doses
      of Zenapax(Registered Trademark) as compared to identical doses of Zenapax(Registered
      Trademark) given in association with (90)Y-armed 7G7/B6, a non-competing antibody to IL-2R
      alpha or in combination with chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Human T-lymphotropic virus type 1 (HTLV-1)-associated adult T cell leukemia/lymphoma (ATL) is
      an aggressive lymphoproliferative disorder.

      Chemotherapy has had limited impact on survival.

      The interleukin 2 receptor alpha (IL-2R alpha) (CD25) is over expressed on ATL cells and the
      smoldering and chronic stages of ATL are often interleukin 2 (IL-2) dependent.

      The monoclonal antibody daclizumab (Zenapax) inhibits interleukin 2 (IL-2) binding to its
      receptor.

      It is hypothesized that daclizumab may inhibit ATL growth.

      Objectives:

      To determine the toxicity and maximum tolerated dose (MTD) of humanized anti-Tac (daclizumab,
      Zenapax) in patients with ATL.

      To define the dose of Zenapax required to saturate IL-2R alpha in patients with ATL.

      To determine the clinical response to humanized (Hu) anti-Tac (Zenapax) of patients with
      Tac-expressing smoldering and chronic stage adult T cell leukemia.

      To determine the serum dieaway curve (pharmacokinetics) of infused humanized (Hu) - anti -
      Tac in patients who have ATL.

      Eligibility:

      Smoldering and chronic stage HTLV-1-associated adult T cell leukemia.

      At least 5 percent of malignant cells in the peripheral blood or lymph nodes must react with
      the anti-Tac (CD25) antibody.

      Age greater than or equal to 10-years-old.

      Patients must have measurable disease.

      Patients with and without prior treatment.

      Patients must have a granulocyte count of greater than or equal to 500/micro L,

      platelets greater than or equal to 25,000/micro L,

      and creatinine less than 3.0 gm/dL.

      Design:

      Phase I patients on cohorts 1-4 received the following: cohort 1: 2 mg/kg over 60 minutes
      intravenously on days 1 and 2; cohort 2: 4 mg/kg over 90 minutes intravenously on day 1,
      single dose; cohort 3: 6 mg/kg over 90 minutes intravenously on day 1, single dose; and
      cohort 4: 8 mg/kg over 90 minutes intravenously on day 1, single dose.

      Patients with smoldering or chronic stage ATL will be treated with intravenous daclizumab 8
      mg/kg on day 0 and weeks 2, 5, 8, 11 and 14.

      Patients achieving a response will continue on treatment with daclizumab 8 mg/kg every 3
      weeks for up to 24 months.

      Patients achieving a complete response (CR) will continue on treatment with daclizumab 8mg/kg
      every 3 weeks for up to 24 months.

      Patients achieving a partial response (PR) will be maintained on daclizumab 8 mg/kg
      administered every 3 weeks provided the PR is maintained and no serious adverse event or
      toxicity related to daclizumab therapy is observed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>21-220 weeks</time_frame>
    <description>Duration of response was defined as the interval from the time response is first achieved to the time progression from the best response is detected. Responses are assessed by a modified World Health Organization (WHO) criteria. Partial response is a reduction of &gt;=50% saturation in the circulating leukemic cell count; complete response is disappearance of all measurable and non-measurable disease lasting more than 1 month; stable disease is patients who did not meet the criteria; and progressive disease is a &gt;=25% increase in leukemic cell count.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>132.6 weeks</time_frame>
    <description>Measured from the time the patient is consented until death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With an Overall Response Rate</measure>
    <time_frame>up to 220 weeks</time_frame>
    <description>Participants overall response rate was defined as complete response (CR) + partial response (PR) from study consent until progression was measured. Responses was assessed by a modified World Health Organization (WHO) criteria. Partial response is a reduction of &gt;=50% saturation in the circulating leukemic cell count; complete response is disappearance of all measurable and non-measurable disease lasting more than 1 month; and progressive disease is a &gt;=25% increase in leukemic cell count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>HTLV-I Infection</condition>
  <condition>T Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>Phase I - 2 mg/kg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - 4 mg/kg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - 6 mg/kg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I - 8 mg/kg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II - 8 mg/kg cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>daclizumab</intervention_name>
    <arm_group_label>Phase I - 2 mg/kg cohort</arm_group_label>
    <arm_group_label>Phase I - 4 mg/kg cohort</arm_group_label>
    <arm_group_label>Phase I - 6 mg/kg cohort</arm_group_label>
    <arm_group_label>Phase I - 8 mg/kg cohort</arm_group_label>
    <arm_group_label>Phase II - 8 mg/kg cohort</arm_group_label>
    <other_name>Zenapax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  ELIGIBILITY CRITERIA:

          -  Population Base.

          -  Patients diagnosed with smoldering or chronic human T-lymphotropic virus type 1
             (HTLV-I)- associated adult T-cell leukemia.

        INCLUSION CRITERIA:

          -  Patients must have serum antibodies directed to HTLV-I.

          -  All patients must have a histologically confirmed diagnosis of adult T-cell
             leukemia/lymphoma.

          -  At least 5 percent of each patient's peripheral blood, lymph node, pulmonary or dermal
             malignant cells must react with the anti-Tac mAb as determined by immunofluorescent
             staining or, alternatively, the serum-soluble interleukin 2 (IL-2) receptor levels
             must be greater than 1,000 units/ml (normal geometric mean, 235; with a 95% confidence
             interval of 112 to 502 units/mL).

          -  Smoldering or chronic stage Tac-expressing adult T-cell leukemia defined by the
             Shimomyama Criteria (37) are eligible.

          -  To be diagnosed as smoldering Adult T-cell Leukemia (ATL), the patient must have a
             normal lymphocyte count (less than 4 times 10^3/mm^3), less than or equal to 5 percent
             abnormal lymphocytes on morphologic examination of the peripheral blood smear or on
             fluorescence activated cell sorting (FACS) analysis (cells with a homogenous staining
             pattern and a greater than 1 log increase in the magnitude of fluorescence emission of
             the anti-Tac peak over background expression),

          -  no hypercalcemia,

          -  lactate dehydrogenase less than or equal to 1.5 times the upper limit of normal,

          -  no lymphadenopathy,

          -  no involvement of extra nodal organs except skin or lung and no malignant pleural
             effusion or ascites.

          -  If the abnormal lymphocyte count is less than 5 percent, the patient must have at
             least one histologically proven skin ATL lesion to be diagnosed as smoldering ATL.

          -  Patients with &gt;5% of circulating lymphocytes that are abnormal are considered to have
             measurable disease.

          -  The patient must have a granulocyte count of at least 500/mm^3 and a platelet count of
             25,000/mm^3.

          -  Patients must have a creatinine of less than 3.0 mg/dl.

          -  Patients must have a Karnofsky performance score of greater than 60 percent.

          -  ATL patients without, as well as those with, previous chemotherapy will be eligible
             for inclusion in the study.

          -  Patients with previous therapy with a monoclonal antibody including anti-Tac will be
             eligible for the study provided that they do not have a positive HAHA (human antibody
             to humanized anti-Tac) value (i.e., such patients must have a value greater than 250
             ng/ml).

          -  Omission of cytotoxic chemotherapy for ATL for 3 weeks prior to entry into the trial
             is required.

          -  However, patients receiving corticosteroids will not be excluded.

          -  Patients must have a life expectancy of greater than 2 months.

          -  Eligible patients must be greater than or equal to 10 years old.

          -  There is no upper age limit.

          -  Patients over the age of 18 years must be able to understand and sign an Informed
             Consent form.

          -  Eligible minors greater than or equal to 10 years old must give assent to participate
             in this study.

        EXCLUSION CRITERIA:

          -  Patients with symptomatic central nervous system disease that is due to the adult
             T-cell leukemia will be excluded.

          -  However, patients that have both ATL and another HTLV-I-associated disease, tropical
             spastic paraparesis (TSP), will be included.

          -  Furthermore, Tac-expressing T cells may be present in the cerebrospinal fluid (CSF) as
             long as the patient does not have symptomatic central nervous system (CNS) disease.

          -  Pregnant and/or nursing patients are not eligible for the study.

          -  Human immunodeficiency virus (HIV) positive patients are excluded from the study.

          -  Patients with serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic
             transaminase (SGPT) values 5.0-fold greater than the upper limit of normal or
             bilirubin greater than 2.9 mg/dl will be excluded.

          -  If a liver function test is judged to be elevated due to the underlying ATL, this
             parameter will be considered an unevaluable parameter for toxicity determinations.

          -  Acute or Lymphoma stage HTLV-1 associated adult T cell leukemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Waldmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2000-C-0030.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <link>
    <url>http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf</url>
    <description>World Health Organization (WHO)</description>
  </link>
  <reference>
    <citation>KÃ¶hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495-7.</citation>
    <PMID>1172191</PMID>
  </reference>
  <reference>
    <citation>Levy R, Miller RA. Tumor therapy with monoclonal antibodies. Fed Proc. 1983 Jun;42(9):2650-6.</citation>
    <PMID>6343125</PMID>
  </reference>
  <reference>
    <citation>Catane R, Longo DL. Monoclonal antibodies for cancer therapy. Isr J Med Sci. 1988 Sep-Oct;24(9-10):471-6. Review.</citation>
    <PMID>3060441</PMID>
  </reference>
  <reference>
    <citation>Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 1991 Aug 15;147(4):1352-9.</citation>
    <PMID>1869828</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2000</study_first_submitted>
  <study_first_submitted_qc>January 18, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2000</study_first_posted>
  <results_first_submitted>April 23, 2012</results_first_submitted>
  <results_first_submitted_qc>July 2, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2012</results_first_posted>
  <last_update_submitted>August 13, 2012</last_update_submitted>
  <last_update_submitted_qc>August 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Thomas A. Waldmann, M.D./National Cancer Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Interleukin-2 Receptor alpha chain</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>HTLV-I</keyword>
  <keyword>Adult T-Cell Leukemia (ATL)</keyword>
  <keyword>Monoclonal Antibody (Daclizumab, Zenapax)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, T-Cell</mesh_term>
    <mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
    <mesh_term>HTLV-I Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase I - 2 mg/kg Cohort</title>
          <description>2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2</description>
        </group>
        <group group_id="P2">
          <title>Phase I - 4 mg/kg Cohort</title>
          <description>4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
        </group>
        <group group_id="P3">
          <title>Phase I - 6 mg/kg Cohort</title>
          <description>6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
        </group>
        <group group_id="P4">
          <title>Phase I - 8 mg/kg Cohort</title>
          <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
        </group>
        <group group_id="P5">
          <title>Phase II- 8 mg/kg Cohort</title>
          <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not treated- rapidly progressing disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I &amp; II Cohorts (2-8 mg/kg)</title>
          <description>Phase I - 2 mg/kg cohort 2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2 Phase I - 4 mg/kg cohort 4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose Phase I - 6 mg/kg cohort 6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose Phase I - 8 mg/kg cohort 8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose Phase II- 8 mg/kg cohort 8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.37" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Response</title>
        <description>Duration of response was defined as the interval from the time response is first achieved to the time progression from the best response is detected. Responses are assessed by a modified World Health Organization (WHO) criteria. Partial response is a reduction of &gt;=50% saturation in the circulating leukemic cell count; complete response is disappearance of all measurable and non-measurable disease lasting more than 1 month; stable disease is patients who did not meet the criteria; and progressive disease is a &gt;=25% increase in leukemic cell count.</description>
        <time_frame>21-220 weeks</time_frame>
        <population>Phase I is not reported because phase I studies only determine maximum tolerated dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II- 8 mg/kg Cohort</title>
            <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Duration of response was defined as the interval from the time response is first achieved to the time progression from the best response is detected. Responses are assessed by a modified World Health Organization (WHO) criteria. Partial response is a reduction of &gt;=50% saturation in the circulating leukemic cell count; complete response is disappearance of all measurable and non-measurable disease lasting more than 1 month; stable disease is patients who did not meet the criteria; and progressive disease is a &gt;=25% increase in leukemic cell count.</description>
          <population>Phase I is not reported because phase I studies only determine maximum tolerated dose.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="21" upper_limit="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Measured from the time the patient is consented until death.</description>
        <time_frame>132.6 weeks</time_frame>
        <population>Phase I is not reported because phase I studies only determine maximum tolerated dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II- 8 mg/kg Cohort</title>
            <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Measured from the time the patient is consented until death.</description>
          <population>Phase I is not reported because phase I studies only determine maximum tolerated dose.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.6" lower_limit="53.9">The upper end of the confidence interval was not reached because at last follow-up a patient had an ongoing response at last contact.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an Overall Response Rate</title>
        <description>Participants overall response rate was defined as complete response (CR) + partial response (PR) from study consent until progression was measured. Responses was assessed by a modified World Health Organization (WHO) criteria. Partial response is a reduction of &gt;=50% saturation in the circulating leukemic cell count; complete response is disappearance of all measurable and non-measurable disease lasting more than 1 month; and progressive disease is a &gt;=25% increase in leukemic cell count</description>
        <time_frame>up to 220 weeks</time_frame>
        <population>Phase I is not reported because phase I studies only determine maximum tolerated dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase II- 8 mg/kg Cohort</title>
            <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Overall Response Rate</title>
          <description>Participants overall response rate was defined as complete response (CR) + partial response (PR) from study consent until progression was measured. Responses was assessed by a modified World Health Organization (WHO) criteria. Partial response is a reduction of &gt;=50% saturation in the circulating leukemic cell count; complete response is disappearance of all measurable and non-measurable disease lasting more than 1 month; and progressive disease is a &gt;=25% increase in leukemic cell count</description>
          <population>Phase I is not reported because phase I studies only determine maximum tolerated dose.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
        <time_frame>12 months</time_frame>
        <population>Data is not available separately per cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I &amp; II Cohorts (2-8 mg/kg)</title>
            <description>Phase I - 2 mg/kg cohort 2 mg/kg daclizumab over 60 minutes intravenously on days 1 and 2 Phase I - 4 mg/kg cohort 4 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose Phase I - 6 mg/kg cohort 6 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose Phase I - 8 mg/kg cohort 8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose Phase II- 8 mg/kg cohort 8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.</description>
          <population>Data is not available separately per cohort.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase II- 8 mg/kg Cohort</title>
          <description>8 mg/kg daclizumab over 90 minutes intravenously on day 1, single dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular/Arrhythmia -Other (Specify, congestive heart failure (CHF))</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Earache (otalgia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>feet edema mild edema in lower extremities edema legs</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Pain-Other (Specify, sore throat pain ; rt knee pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound-non-infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="25" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Leukocytes (total white blood count (WBC))</sub_title>
                <counts group_id="E1" events="24" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (absolute neutrophil count (ANC)/absolute granulocyte count (AGC))</sub_title>
                <counts group_id="E1" events="22" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>SGOT (aspartate aminotransferase (AST)) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>SGPT (alanine aminotransferase (ALT)) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="4" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal/Genitourinary-Other (Specify, UTI (urinary tract infection))</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dysuria (painful urination)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary-Other (Specify, URI (upper respiratory infection))</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify, Lesions Lt elbow)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Photosensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was closed to accrual since the cessation of the production of daclizumab.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas Waldmann, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institues of Health</organization>
      <phone>301-496-6653</phone>
      <email>tawald@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

